Study of Lymphatic Drainage Mapping in Oropharyngeal Cancers

Status Completed

Clinical Trial Summary

The purpose of the study is to see how practical it is to inject a radiotracer called 99m-Technetium Sulfur Colloid around the tumors for the imaging of patients with oropharyngeal cancer.

Clinical Trial Description

This study will evaluate a technique called lymphatic drainage mapping. This is a technique where a radiotracer (a radioactive material that can be seen with a special computed tomography [CT] scanner to create 3D images) is injected into a vein around the tumour, either with local anesthesia or under general anesthesia. The radiotracer that will be used for the lymphatic drainage mapping is called 99m-Technetium Sulfur Colloid. Images will be taken of neck to detect the movement of the radiotracer. This will allow the doctors to see the drainage pattern of the lymph nodes in the neck. The information from this study will be used to better understand the tendency for oropharyngeal cancers to spread to lymph nodes. In addition, the information from this clinical trial will be used in future clinical studies to help specialists identify strategies to help plan treatment based on this type of imaging study. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05055206
Study type	Interventional
Source	University Health Network, Toronto
Contact
Status	Completed
Phase	N/A
Start date	September 13, 2021
Completion date	October 31, 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04444869` - Testing Less Intensive Radiation With Chemotherapy to Treat Low-risk Patients With HPV-positive Oropharyngeal Cancer	Phase 2
Completed	`NCT00158678` - IMRT Plus Cisplatin Versus Conventional Radiotherapy Plus Cisplatin in Stage III-IV HNSCC	Phase 3
Completed	`NCT04567082` - Proteome- and Methylation Profiles in Oropharyngeal Cancer
Recruiting	`NCT06016699` - Immunological Function After Radiation With Either Proton or Photon Therapy
Withdrawn	`NCT04001413` - Therapy for High-Risk HPV 16-Positive Oropharynx Cancer Patients	Phase 2
Completed	`NCT03435471` - Outcomes of Prophylactic Swallowing Therapy in Patients Undergoing Definitive Chemoradiation for Head and Neck Cancer	N/A
Recruiting	`NCT04359199` - QUantitative Assessment of Swallowing After Radiation (QUASAR)
Recruiting	`NCT05793151` - Multi-Site Trial of Navigation vs Treatment as Usual for Delays in Starting Adjuvant Therapy	N/A
Active, not recruiting	`NCT02908477` - Evaluation of De-escalated Adjuvant Radiation Therapy for Human Papillomavirus (HPV)-Associated Oropharynx Cancer	Phase 3
Active, not recruiting	`NCT00232960` - Postoperative Radiotherapy According to Molecular Analysis of Surgical Margins of Oral and Oropharyngeal SCC	N/A
Completed	`NCT05698667` - Outpatient Ultrasound for the Diagnostic Work-up of Oropharynx Cancer	N/A
Recruiting	`NCT05757817` - Evaluation of the Benefit of a New Surgical Procedure According to IDEAL Recommendations for ORL Cancer Patients: the External Pudendal Flap Used as a New Free Flap for Oral Cavity/Oropharyngeal Reconstruction to Limit Donor Site Sequelae	N/A
Active, not recruiting	`NCT02586207` - Pembrolizumab in Combination With CRT for LA-SCCHN	Phase 1
Completed	`NCT01108042` - TPF-Induction Chemotherapy of Oropharyngeal and Cavity of the Mouth Cancer	Phase 1/Phase 2
Completed	`NCT03342378` - PET-MRI Assessment of Early Tumor Response to Predict Outcomes of HPV-Positive Oropharynx Cancer Patients
Active, not recruiting	`NCT03416153` - Individualized Adaptive De-escalated Radiotherapy for HPV-related Oropharynx Cancer	Phase 2
Terminated	`NCT01066741` - Prevention of Radiation-induced Severe Oral Mucositis in Oral Cavity, Oropharynx, Hypopharynx, and Cavum Cancer	Phase 3
Completed	`NCT03418792` - Functional Sparing of Salivary Glands Using MRI Sialography for Patients Undergoing Definitive Radiation Therapy for Head and Neck Cancers of the Oropharynx	N/A
Recruiting	`NCT06088381` - Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL)	Phase 2
Recruiting	`NCT05686226` - E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers	Phase 2